DCTH 1.32...Information post about upcoming catalysts in the 1H2013 that could possibly move the stock higher. The company expects an FDA Advisory Committee meeting to be scheduled sometime in May 2013 and was given a PDUFA date of June 15, 2013 for regulatory decision on marketing of its Chemosaturation system (CHEMOSTAT) for the treat of inresectable metastatic ocular melanoma.The 52K tading range is 1.04-4.74 Information in regards to the recent change to label indication: http://finance.yahoo.com/news/delcath-provides-nda-submission-chemosaturation-213602694.html
* The company recently executed a $35 MILLION COMMITTED EQUITY FINANCING FACILITY WITH TERRAPIN OPPORTUNITY, L.P. million dollar committed equity financing facility with Terrapin Opportunity, L.P.
With $28.3 million in cash and equivalents at September 30, 2012, and an additional $21.5 million currently available under our At-The-Market program, we believe the CEFF provides us with the resources and flexibility required to execute our operation plan through our June PDUFA goal date and well beyond.
Disclaimer: Opinions expressed in this post are just that. Opinions. I am not a licensed broker.Please weigh the strategies discussed here carefully against what you are willing to risk. Please do your own due diligence before buying or selling ANY SECURITY in the open market, there are no guarantees.
AI
